The Cautionary Tale
The protocol illusion: why dosing math can't fix a vial nobody tested
Every serious Melanotan II guide on the internet has the same shape. A starting dose. A titration schedule — go slow, increase weekly, never daily. A maintenance plan. A reconstitution section with milligrams per millilitre worked out to a decimal. The formatting is clinical. The tables are aligned. The whole artefact reads like something a pharmacologist signed off on.
None of them were. This file is about what the genre is, and what it cannot be. The numbers are not reproduced here — that would turn a story about the guides into a guide — but their structure is the story.
The genre is real, and it has been studied
These guides are not random. They are a genre with conventions, and academics have read it the way this site is reading it. A 2021 qualitative study in Dermatology — Gilhooley, Daly, and McKenna — extracted Melanotan II discussions from UK and Ireland forums between January 2016 and October 2017 and examined how users talk about the compound. The pattern they found is the one this file describes: users construct dosing regimens, share titration advice, and police one another’s protocols with the confidence of people administering a known drug.
The confidence is the product. In a space where no regulator has ever set a standard for the substance, the forum protocol performs the function that approval, labelling, and prescribing normally perform. It converts an unknown into a schedule.
A protocol is a contract. The vial never signed it.
Here is what a dosing protocol actually is, in a regulated medicine. It is not a number. It is a contract with three parties: a label — a verified statement of what the vial contains, in what concentration, made under audited conditions; a pharmacology — measured absorption, distribution, and clearance in real patients, from which the dose was derived; and a prescriber — someone licensed to adjust the contract when the patient doesn’t match the average.
The gray-market guide borrows the vocabulary of all three parties and supplies none of them. The label is a disclaimer that says not for human consumption — a statement the transaction itself treats as theatre. The pharmacology is forum anecdote, self-reported by people who have no way of knowing what they actually took. The prescriber is a stranger in a reply thread.
The arithmetic is real. The premises are fiction. A titration schedule computed against a 30-milligram label is a precise calculation of a guess.
The label is a suggestion — measured, in milligrams
This is not a philosophical point about the gray market. It is a laboratory result.
Australia’s regulator seized nasal-spray bottles labelled “30 mg” and had five of them tested. The Melanotan II content came back between 22 and 54 milligrams, against a labelled 20-millilitre volume. That is the TGA’s own finding, published on its own letterhead, in August 2026 — and it is the single most important number in this file.
Take the widest spread a protocol can imagine and compare it with that result. The guide’s precision operates at the second decimal place. The vial’s actual content varies by a factor of more than two, in products that carried a printed specification. No reconstitution math survives contact with a label that is off by 80 percent. Every number downstream of it — every “milligram per injection,” every weekly total — inherits the error it was computed from.
The vial problem is usually told as a purity story (you can’t know what’s in the vial). The TGA finding makes it a quantity story too. Even the buyers who got pure product got an unknown dose of it. The protocol is a dial attached to nothing.
The developers ran a protocol. They stopped.
The irony the genre never carries: the molecule has been inside a real protocol. The Arizona team self-administered it under observation, and later the intranasal pharmaceutical version of this drug class went through clinical testing with actual dose-finding, actual monitoring, and actual stopping rules.
The intranasal program is the tell. It was abandoned — the blood-pressure effects of a non-selective melanocortin agonist delivered that way made the route untenable, which is why the approved cousins went to an implant and an auto-injector instead (the middle-ground agonist already exists). A protocol, run properly, has the power to say stop. It said stop.
The forum genre inverts the relationship. It takes the very molecule the formal system tested and set aside, and rebuilds around it an informal system whose defining feature is that it cannot say stop — no adverse event ever pauses a thread, no safety signal rewrites a stickied guide. When something goes wrong, the genre’s answer is never that the protocol failed. It is that the batch was bad, or the user titrated too fast. The numbers survive every outcome, because the numbers were never doing any work.
What the guides are actually selling
Strip the formatting away and the genre sells one thing: the feeling that risk is being managed.
Titrating slowly, measuring millilitres, keeping a log — these are the gestures of control, and they feel like control because in a regulated system they are. The guides import them intact and assume the safety travels with the syntax. It does not. Management requires something to manage against: a known concentration, a known impurity profile, a known dose-response. The vial offers none of those, so the protocol manages nothing. It is ritual in the shape of rigor.
The honest version of every one of these guides would be two sentences long: the contents of this vial are unknown in amount and purity, so no dose can be specified, and every number that follows is a guess with a decimal point. No guide ever runs that version, because it cannot be formatted into a table.
The enforcement file keeps the dates of what regulators have done about the supply. This file records the other half: the demand side built a control system out of typography. The TGA measured the label. It was off by a factor of two. Between those two facts is everything the protocol genre cannot survive being asked — and the reason the market has never once tried to answer it.